MDVN 112.77 Medivation Inc $MDVN Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 12:35 PM

MDVN 112.77 Medivation Inc $MDVN Hit a 52 week high of 113.61 Currently at 112.77 +7.82 +7.45% With a day low of 102.04 and a total volume of 3,281,900.

MDVN Medivation Inc Recent Headline News

5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 33 mins ago
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 112.77 (+7.82), JNJ: 108.20 (-0.81), BIIB: 320.75 (-2.72), PTLA: 27.39 (-0.33), GILD: 106.45 (-0.49), CELG: 106.45 (-0.69)

Look for Shares of Medivation to Potentially Pullback after Yesterday's 7.45% Rise
Comtex SmarTrend(R) - Fri Nov 07, 3:46PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $102.04 to a high of $113.61. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $106.79 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 112.77 (+7.82)

Clarification: Earns-Medivation story
AP - Fri Nov 07, 11:53AM CST
SAN FRANCISCO (AP) — In a story Nov. 7, The Associated Press reported that Medivation Inc. missed third-quarter earnings and revenue expectations based on the average of seven forecasts from Zacks Investment Research. The story was later updated to reflect that the company beat expectations based on the average of 18 estimates from FactSet.
MDVN: 112.77 (+7.82)

Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 11:08AM CST
Medivation's (MDVN) Xtandi should see strong uptake in the chemo-naive patient population from the fourth quarter.
CYTK: 4.10 (-0.15), MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72)

Medivation Hits High After Q3 Earnings Beat
at Investor's Business Daily - Fri Nov 07, 10:15AM CST
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation's earnings totaled 96 cents a share, reversing a year-earlier loss and...
MDVN: 112.77 (+7.82), AOL: 42.68 (+0.45), AZN: 72.88 (+0.03)

Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Marketwired - Thu Nov 06, 3:13PM CST
Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the third quarter ended September 30, 2014. U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $181.4 million (+67% vs. prior year). Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $119.6 million.
MDVN: 112.77 (+7.82)

Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Wed Nov 05, 3:11PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 112.77 (+7.82)

3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 112.77 (+7.82), ENDP: 68.96 (-1.23), AUXL: 32.75 (-0.52), SHPG: 198.58 (-1.37), DNDN: 0.94 (+0.11), SNSS: 1.63 (-0.05), ABBV: 61.50 (-1.21), SNY: 45.69 (-0.17), MNKD: 5.78 (+0.07), XOMA: 3.81 (-0.31)

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
at The Street - Wed Nov 05, 7:00AM CST
The diversification away from Xtandi has only just begun.
MDVN: 112.77 (+7.82)

Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 112.77 (+7.82), ACT: 245.91 (-4.47), PRGO: 155.77 (+3.28), ALNY: 95.84 (+2.93)

Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.70 (-0.07), MDVN: 112.77 (+7.82), ALNY: 95.84 (+2.93), HUM: 130.58 (-9.29)

Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 04, 8:00AM CST
Geron's (GERN) third quarter results were totally overshadowed by the removal of the full clinical hold on the IND application for imetelstat.
CYTK: 4.10 (-0.15), MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), GERN: 2.33 (-0.07)

Geron Corporation (GERN) Looks Strong: Stock Up 25.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:44AM CST
Geron Corporation (GERN) was a big mover last session, as the company saw its shares surge nearly 26% on the day
MDVN: 112.77 (+7.82), ONCY: 0.70 (+0.08), GERN: 2.33 (-0.07), ILMN: 186.35 (-3.52)

Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:00PM CST
Hospira (HSP), which is scheduled to report third-quarter 2014 results on Nov 6, had posted a positive earnings surprise of 28.57%.
MDVN: 112.77 (+7.82), ACT: 245.91 (-4.47), ALNY: 95.84 (+2.93), HSP: 56.32 (-0.32)

Will DaVita Healthcare (DVA) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:40PM CST
DaVita Healthcare Partners, Inc. (DVA) is set to report third-quarter 2014 earnings on Nov 6, 2014.
MDVN: 112.77 (+7.82), AMSG: 51.50 (+0.16), DVA: 74.49 (-3.54), ALNY: 95.84 (+2.93)

Seattle Genetics Gains on Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 11:50AM CST
Seattle Genetics, Inc. (SGEN) reported a loss of 13 cents per share in the third quarter, narrower than the Zacks Consensus Estimate of a loss of 25 cents.
MDVN: 112.77 (+7.82), BIIB: 320.75 (-2.72), SGEN: 36.05 (+1.20), GILD: 106.45 (-0.49)

Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:39AM CST
Prosensa Holding N.V. (RNA) was a big mover last session, as its shares rose nearly 10% on the day.
MDVN: 112.77 (+7.82), MACK: 8.70 (-0.07), RNA: 12.14 (+0.08), ILMN: 186.35 (-3.52)

Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:51AM CST
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as its shares rose nearly 7% on the day.
MDVN: 112.77 (+7.82), MACK: 8.70 (-0.07), ALDR: 16.57 (-0.25), ILMN: 186.35 (-3.52)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Potatoes vs. Candy: Halloween's Spuddy Surprise

When Halloween rolls around, you expect rabid kids clamoring for candy corn and chocolate bars. But this year, Idaho threw a spud into the sweets machine. Idaho's Potatoes Steal the Show In an unexpected twist, the Idaho Potato Commission ran a zany experiment on Halloween: kids had to choose between their beloved Halloween candy and a genuine Idaho potato. Imagine the...

2026 Rawlings Gold Glove Award Winners Announced

Fielding Excellence on Display: The 2026 Rawlings Gold Glove Awards The Rawlings Gold Glove Awards have once again shone the spotlight on baseball's defensive maestros. Announced by Rawlings Sporting Goods Company, Inc., on November 1, 2026, this year's winners include 11 seasoned veterans and nine greenhorns who claimed their first-ever Gold Gloves. Unveiled during a...

Double Down for Veterans Raises $20 Million Goal

Helping Veterans: A Call That Never Fades If there's one thing that never changes, it's the enduring need to support those who have served. Semper Fi & America's Fund has been at the forefront of this mission for over a decade, and their annual Double Down for Veterans Match Campaign is nothing short of a testament to unwavering commitment. Kicking off for the 15th time,...

Nanchang Expo Showcases Future of Aviation and Space

Aviation Dreams Take Off in Nanchang Not every day you see an expo spanning 30,000 square meters focused on aviation, especially where East meets innovation—Nanchang, the beating heart of Jiangxi Province, China, is where it's all happening this time around. October 31, 2026, saw the city launching not rockets but the 2026 Nanchang Aviation Industry Expo, and folks,...

Veteran Surge in 2026 Midterm Elections: A New Wave

A Swell of Veteran Candidates Hits the Midterm Shores Just when you think you've seen it all in politics, here comes another twist. As the 2026 midterms gear up, an impressive 258 military veterans are throwing their hats into the congressional ring. That's a jump up from 213 just two years back, and let me tell you, it's not just a numbers game—it's a sea change. Women...

Orthocell's Remplir™ Hits Record U.S. Sales in October

Orthocell's October Surprise with Remplir™ Sales Well, isn't this a breath of fresh air? Orthocell Limited just reported a staggering rise in its U.S. Remplir™ sales for October 2026. We're talking 92 units shifting off the shelves, pulling in a tidy AU$279,000. That's an 84% leap compared to the average monthly sales of 50 units in Q1 FY27. It seems the company's...

TESSAN and Jamie Leibert's Daring Alpine Documentary Launch

Steps Beyond the Obvious Adventure Launching headlong into the unknown—literally and figuratively—is what the documentary Jump Into The Unknown captures. TESSAN and Jamie Leibert have peeled back the curtain on adventure, showing us that it’s not just about the destination, but every twist, turn, and recalibrated step in between. The Backstory Behind Every Jump...

Navigating Underinsured Motorist Coverage Woes

When the Rubber Hits the Road: Coverage Gaps Ever been in a fender bender and found out the other driver’s insurance barely covers a dent, let alone a serious crash? Believe me, it's no picnic. Chuck Clark from HelloNation digs into this with a deep dive on underinsured motorist coverage, or UIM for short. It's an eye-opener—especially if you're assuming your auto...

One Stop Swap eyes school fundraising for growth

Transforming Fundraising with a Marketplace Twist Sometimes the real treasures are not tucked in textbooks but found in cluttered closets and basements. Enter One Stop Swap with a big idea—they're cooking up a fundraising strategy for schools that could shake things up by helping families sell their unused stuff. It's got that grassroots vibe with the potential to carve...

UPM-Kymmene Finalizes Demerger: WISA Group to Nasdaq

UPM-Kymmene Shakes Things Up Here's the meat and potatoes: UPM-Kymmene Corporation is going through a big change. They've decided to cut a part of themselves off and send it out into the world. This partial demerger has been registered, and now WISA Group Plc is stepping out from UPM's shadow. Where to? They're headed for the big league, getting listed on Nasdaq Helsinki....